CHAMPLAIN was a prospective, phase 2, multicenter, open-label, 26-week study enrolling 55 patients with treatment-resistant DME and a history of pars plana vitrectomy in the study eye; most of the study eyes (n=42) were pseudophakic at baseline. All eyes received a single injection of 0.7 mg dexamethasone intravitreal implant.

Quiz Module 10.6

1. What was the focus of the CHAMPLAIN study?

2. In vitrectomized eyes, dexamethasone intravitreal implant was shown to improve what?